Aktienanalyse zu SCYNEXIS Inc (SCYX)SCYXSCYNEXIS Inc

SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

SCYNEXIS Inc (SCYX) is a good buy right now, trading at $3.81 with a forward P/E of 1.85, suggesting significant growth potential. The stock is currently near its 52-week low of $3.53, which presents a favorable entry point. Despite a recent 20-day decline of 24.25%, the company has secured non-dilutive funding from the Biomedical Advanced Research and Development Authority, which is expected to enhance its financial stability and growth prospects. However, the main risk is the negative earnings trend, with an EPS estimate of -0.40 for the upcoming earnings report on November 4, 2026.

7 analysts cover SCYX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 3.50.